Dawn McGuire

Avigen, Inc. produces and sells drugs, animal health products, and chemicals. The firm also develops and commercializes small molecules of therapeutics and biologics for use in the treatment of serious neurological and neuromuscular disorders. The company was founded in 1992 and is headquartered in La Jolla, CA.

Pepgen Corp. was a biopharmaceutical company. Its product was Tauferon. The company was founded by C. P. Liu in 1992 and was headquartered in Alameda, CA.

Acologix, Inc. develops and commercializes medicines. The company was founded by Yoshinari Kumagai in 1992 and is headquartered in Hayward, CA.

Eunoe, Inc. provides medical device therapy to treat Alzheimer’s Disease and company focused on the treatment of neurological disorders through the management of cerebrospinal fluid. The company is located in Pleasanton, CA.

Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX.

Alpha Omega Alpha Honor Medical Society is a national medical honor society founded in 1902. The non-profit company is based in Menlo Park, CA. The society's mission is to foster the development of the next generation of medical researchers by recognizing high educational achievement, honoring gifted teaching, encouraging the development of leaders in academia and the community, and supporting the improvement of care for all.

Elan Biopharmaceuticals, Inc. distributes drugs and pharmaceuticals. It currently distributes three concentrated morphine sulfate oral solutions which include RoxanolT CII, Roxanol-TT CII and Roxanol 100T CII. Elan Biopharmaceuticals is located in San Diego, CA.

OrthoTrophix, Inc. is a privately held American biopharmaceutical company founded in 2011 by Dawn McGuire, Yoshinari Kumagai, and David M. Rosen. The company is based in the area and focuses on the development and commercialization of a first-in-class disease modifying osteoarthritis drug (DMOAD). Its primary focus has been regeneration and repair of cartilage and underlying bones in the knee and other joints with its novel proprietary compounds. Yoshinari Kumagai has been the CEO since 2011.